Subsequently, other PARP inhibitors combination Talazoparib + Enzalutamide, Niraparib + Abiraterone Acetate + Prednisone, were approved in 2023 for treating patients with metastatic castration-resistant prostate cancer with alterations in BRCA1, BRCA2, and HRR deficiency gene mutation [5]. This evidence concerns the gene BRCA1 and prostate cancer.